NCT06433726View on ClinicalTrials.gov

A Phase l Study of By101921, an Oral PARP7 Inhibitor, in Patients With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 11, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions
Solid Tumor, Adult
Interventions
DRUG

BY101921 tablets

An oral PARP7 Inhibitor

Trial Locations (1)

250117

RECRUITING

Cancer Hospital Affiliated to Shandong First Medical University / Shandong Cancer Research Institute / Shandong Cancer Hospital, Jinan

Sponsors
All Listed Sponsors
lead

Chengdu Baiyu Pharmaceutical Co., Ltd.

INDUSTRY